Clinical trials: RA - Rheumatoid Arthritis
Rheumatoid Arthritis
A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis
The primary purpose of the study is to evaluate the effect of ASP1707 twice daily on the pharmacokinetics of once weekly oral methotrexate (MTX).
- Trial name
- NCT02867306
- Testing
- ASP1707, methotrexate (MTX)
- Where
- Moldova
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Rheumatoid Arthritis
Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether the study drug, BMS-986142, is safe and effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate response to methotrexate or methotrexate and…
- Trial name
- NCT02638948
- Testing
- BMS-986142, Methotrexate
- Where
- 104 sites in United States, Argentina and 15 more
- Volunteers
- 508 people
- Sponsor
- Bristol-Myers Squibb
Degenerative Osteoarthritis, Rheumatoid Arthritis
VEGA Prospective Kiel
Voluntary Post-Marketing Clinical Follow-up (PMCF) as part of the post marketing surveillance plan for the product under investigation.
- Trial name
- NCT02802085
- Testing
- VEGA Knee
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Aesculap AG
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) and inhibition of radiographic progression in patients with active RA who are…
- Trial name
- NCT01604343
- Testing
- Sirukumab
- Where
- 156 sites in United States, Bulgaria and 16 more
- Volunteers
- 1,670 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics (how the drug effects certain target sites of activity in the body) of escalating doses of oral PF-04308515 in healthy…
- Trial name
- NCT01101932
- Testing
- PF-04308515, PF-04308515 Tablet
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
This multicenter study with a randomized, double-blind, parallel-group phase will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in…
- Trial name
- NCT01587989
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 13 sites in Austria
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients
The purpose of this study is to determine if GSK706769 can maintain clinical remission established by Enbrel after withdrawal of Enbrel in rheumatoid arthritis patients.
- Trial name
- NCT00979771
- Testing
- GSK706769
- Where
- Netherlands
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.
- Trial name
- NCT04333771
- Testing
- SHR0302
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Osteoarthritis, Hip, Rheumatoid Arthritis
G7 Freedom Constrained Vivacit-E Liners
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures
- Trial name
- NCT05587244
- Testing
- Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners
- Where
- 10 sites in United States
- Volunteers
- 202 people
- Sponsor
- Zimmer Biomet
Rheumatoid Arthritis
A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects
This study is a randomized, double-blind and placebo-controlled trial with healthy subjects. There are 6 Groups as follows: 5mg, 15mg, 30mg, 50mg, 75mg, 100mg, and each group includes12 people.
- Trial name
- NCT02460393
- Testing
- Humanized TNFα monoclonal antibody
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Rheumatoid Arthritis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.
A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD9567.
- Trial name
- NCT02760316
- Testing
- AZD9567 10 mg, AZD9567 20 mg, AZD9567 40 mg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Study of GS-0151 in Participants With Rheumatoid Arthritis
The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is.
- Trial name
- NCT06902519
- Testing
- GS-0151
- Where
- 35 sites in United States, Georgia and 4 more
- Volunteers
- 65 people
- Sponsor
- Gilead Sciences
Arthritis, Traumatic Arthritis
The Medacta International GMK Sphere Post-Marketing Surveillance Study
This is a Post-Marketing Surveillance of GMK Sphere knee prosthesis.
- Conditions
- Arthritis, Traumatic Arthritis, Rheumatoid Arthritis, Poly-arthritis
- Trial name
- NCT02199600
- Testing
- GMK Sphere Knee Replacement
- Where
- 4 sites in Belgium, United Kingdom
- Volunteers
- 500 people
- Sponsor
- Medacta International SA
Rheumatoid Arthritis
Safety Profile of Nulojix in Home Infusion Settings
The study is a retrospective cohort study that utilizes medical records from the BiologicTx. Data accrual starts upon initial home infusion nurse visit until the most recent home infusion nurse visit.
- Trial name
- NCT02500498
- Testing
- Nulojix
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Glenohumeral Osteoarthritis, Proximal Humerus Fracture
Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Shoulder Prosthesis System
This study is designed as a prospective, multicenter, observational post-market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the Tipmed™ Shoulder Prosthesis System at 12 months postoperatively.
- Conditions
- Glenohumeral Osteoarthritis, Proximal Humerus Fracture, Rotator Cuff Arthropathy, Rheumatoid Arthritis
- Trial name
- NCT07678034
- Testing
- Tipmed™ Reverse Shoulder Prosthesis System, Tipmed™ Shoulder Prosthesis System (Hemiarthroplasty Configuration)
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- TIPMED Medical Device Manufacturing Ltd. Co.
Rheumatoid Arthritis
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
An observational study to describe the effectiveness, safety, and patient-reported outcomes in patients with moderate to severe active rheumatoid arthritis (RA) receiving filgotinib in real-world setting.
- Trial name
- FILOSOPHY (NCT04871919)
- Testing
- Filgotinib
- Where
- 89 sites in Belgium, Germany and 4 more
- Volunteers
- 1,304 people
- Sponsor
- Alfasigma S.p.A.
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
This is a Phase 1 single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06835375 in subjects with seropositive SLE or RA.
- Trial name
- NCT03334851
- Testing
- PF-06835375
- Where
- 17 sites in United States
- Volunteers
- 74 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
Primary Objective: To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.
- Trial name
- NCT01768572
- Testing
- sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine
- Where
- 78 sites in United States, Argentina and 17 more
- Volunteers
- 202 people
- Sponsor
- Sanofi
Arthritis, Rheumatoid
Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis
Study to determine the efficacy (including American College of Rheumatology (ACR) 20 response rate), safety, and pharmacokinetics of BIRB 796 BS as monotherapy in patients with moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT02214888
- Testing
- BIRB 796 BS, low dose, BIRB 796 BS, high dose
- Volunteers
- 170 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study in healthy volunteers, multiple dose study in patients with rheumatoid arthritis and multiple dose study in healthy volunteers.
- Trial name
- NCT01741493
- Testing
- ABT-494, Tofacitinib
- Where
- 5 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.